Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Anna Sureda

Showing results (211-220 of 380) with videos related to

Pageof 38
Sort By:
Bone Marrow Transplantation|February 12, 2025
The 2023 EBMT report on hematopoietic cell transplantation and cellular therapies. Increased use of allogeneic HCT for myeloid malignancies and of CAR-T at the expense of autologous HCTJakob R Passweg, Helen Baldomero, Marina Atlija, et al.
The Lancet. Haematology|January 6, 2024
Prophylaxis and management of graft-versus-host disease after stem-cell transplantation for haematological malignancies: updated consensus recommendations of the European Society for Blood and Marrow TransplantationOlaf Penack, Monia Marchetti, Mahmoud Aljurf, et al.
Blood|February 26, 2005
Outcomes for reduced-intensity allogeneic transplantation for multiple myeloma: an analysis of prognostic factors from the Chronic Leukaemia Working Party of the EBMTCharles Crawley, Marc Lalancette, Richard Szydlo, et al.
Bone Marrow Transplantation|May 27, 2026
The 2024 EBMT activity report: crossing one million HCTs and 20,000 CAR-T. A landmark in cellular therapyRaffaella Greco, Isabel Sánchez-Ortega, Antonio M Risitano, et al.
Bone Marrow Transplantation|June 19, 2026
The impact of IPI risk factors on CAR T-cell therapy or allogeneic stem cell transplantation for treatment of relapsed or refractory large B-cell lymphoma (LBCL)Anna Ossami Saidy, Ariane Boumendil, Peter Dreger, et al.
Frontiers in Immunology|October 13, 2023
Organ complications after CD19 CAR T-cell therapy for large B cell lymphoma: a retrospective study from the EBMT transplant complications and lymphoma working partyOlaf Penack, Christophe Peczynski, Christian Koenecke, et al.
Bone Marrow Transplantation|March 11, 2026
An extraction pipeline for analysis of hematopoietic stem cell transplantation dataErik G J von Asmuth, Constantijn J M Halkes, Jurjen Versluis, et al.
Cancer Reports (Hoboken, N.J.)|March 3, 2021
The direct and indirect effects of COVID-19 pandemic in a real-life hematological settingMaria Condom, Alberto Mussetti, Clara Maluquer, et al.
Blood Cancer Journal|April 30, 2021
Correction: Allogeneic transplantation in elderly patients ≥65 years with non-Hodgkin lymphoma: a time-trend analysisNirav N Shah, Kwang Woo Ahn, Carlos Litovich, et al.
Leukemia|April 13, 2022
The outcome of patients with Hodgkin lymphoma and early relapse after autologous stem cell transplant has improved in recent yearsAli Bazarbachi, Ariane Boumendil, Hervé Finel, et al.
Pageof 38

Showing results (211-220 of 380) with videos related to

Sort By:
Pageof 38
Bone Marrow Transplantation|February 12, 2025
The 2023 EBMT report on hematopoietic cell transplantation and cellular therapies. Increased use of allogeneic HCT for myeloid malignancies and of CAR-T at the expense of autologous HCTJakob R Passweg, Helen Baldomero, Marina Atlija, et al.
The Lancet. Haematology|January 6, 2024
Prophylaxis and management of graft-versus-host disease after stem-cell transplantation for haematological malignancies: updated consensus recommendations of the European Society for Blood and Marrow TransplantationOlaf Penack, Monia Marchetti, Mahmoud Aljurf, et al.
Blood|February 26, 2005
Outcomes for reduced-intensity allogeneic transplantation for multiple myeloma: an analysis of prognostic factors from the Chronic Leukaemia Working Party of the EBMTCharles Crawley, Marc Lalancette, Richard Szydlo, et al.
Bone Marrow Transplantation|May 27, 2026
The 2024 EBMT activity report: crossing one million HCTs and 20,000 CAR-T. A landmark in cellular therapyRaffaella Greco, Isabel Sánchez-Ortega, Antonio M Risitano, et al.
Bone Marrow Transplantation|June 19, 2026
The impact of IPI risk factors on CAR T-cell therapy or allogeneic stem cell transplantation for treatment of relapsed or refractory large B-cell lymphoma (LBCL)Anna Ossami Saidy, Ariane Boumendil, Peter Dreger, et al.
Frontiers in Immunology|October 13, 2023
Organ complications after CD19 CAR T-cell therapy for large B cell lymphoma: a retrospective study from the EBMT transplant complications and lymphoma working partyOlaf Penack, Christophe Peczynski, Christian Koenecke, et al.
Bone Marrow Transplantation|March 11, 2026
An extraction pipeline for analysis of hematopoietic stem cell transplantation dataErik G J von Asmuth, Constantijn J M Halkes, Jurjen Versluis, et al.
Cancer Reports (Hoboken, N.J.)|March 3, 2021
The direct and indirect effects of COVID-19 pandemic in a real-life hematological settingMaria Condom, Alberto Mussetti, Clara Maluquer, et al.
Blood Cancer Journal|April 30, 2021
Correction: Allogeneic transplantation in elderly patients ≥65 years with non-Hodgkin lymphoma: a time-trend analysisNirav N Shah, Kwang Woo Ahn, Carlos Litovich, et al.
Leukemia|April 13, 2022
The outcome of patients with Hodgkin lymphoma and early relapse after autologous stem cell transplant has improved in recent yearsAli Bazarbachi, Ariane Boumendil, Hervé Finel, et al.
Pageof 38